Physician profile
Alan Kaufman
NPI 1437150513
$59,840.49
in general payments reported to CMS, 2019-2025
33 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $3,432 · 2021: $13K · 2022: $9,142 · 2023: $2,487 · 2024: $3,636 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,497 · Consulting Fee: $1,476 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,496.93 |
| Consulting Fee | $1,475.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33,710.78 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Optinose US, INC. | $5,527.67 | 2019-2024 | |
| Genentech USA, INC. | $3,099.94 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $2,815.41 | 2019-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $1,958.81 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $1,830.48 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $1,646.42 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $1,343.41 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Genzyme Corporation | $1,327.74 | 2019-2025 | |
| Pfizer INC. | $977.22 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $676.77 | 2019-2025 | Dupixent |
| Halozyme INC | $525.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $512.30 | 2019-2025 | |
| Beigene USA, INC. | $475.00 | 2024 | |
| Adma Biomanufacturing LLC | $385.63 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $348.50 | 2019-2025 | Xolair |
| Incyte Corporation | $339.61 | 2022-2025 | Opzelura |
| Csl Behring | $337.22 | 2019-2021 | |
| Dermavant Sciences, INC. | $292.49 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.50 | 2019-2021 | |
| Blueprint Medicines Corporation | $260.60 | 2024-2025 | Ayvakit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $137.59 | 2019 | |
| Shire North American Group INC | $121.87 | 2019 | |
| Allergan, INC. | $115.82 | 2020 | |
| Mylan Specialty L.P. | $111.51 | 2020 | |
| Sunovion Pharmaceuticals INC. | $111.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2025 | Takhzyro |
| Greer Laboratories, INC. | $95.57 | 2025 | Oralair |
| Kaleo, INC. | $73.57 | 2019 | |
| Circassia INC. | $43.21 | 2019 | |
| Leo Pharma INC. | $12.48 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.